Contact
Please use this form to send email to PR contact of this press release:
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
TO:
Please use this form to send email to PR contact of this press release:
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
TO: